

**Final Agenda**  
**44<sup>th</sup> meeting of the Committee for Risk Assessment**

**27 February – 9 March 2018**

**ECHA Conference Centre (Annankatu 18, Helsinki)**

**Tuesday 27 February starts at 14.00**  
**Friday 9 March ends at 13.00**

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

***RAC/A/44/2018***  
***For adoption***

**Item 3 – Declarations of conflicts of interest to the Agenda**

**Item 4 – Appointment of (co-)rapporteurs**

- a) Appointment of (co-)rapporteurs for CLH dossiers, restriction dossiers, authorisation applications, DNEL/dose-response relationships, Article 95(3) requests and Article 77(3)(c) requests

***RAC/44/2017/01***  
***(restricted)***  
***Room document***  
***For agreement***

## **Item 5 – Report from other ECHA bodies and activities**

- a) Report on RAC 43 action points, written procedures and update on other ECHA bodies

**RAC/44/2017/02**

**Room document**

**For information**

- b) RAC workplan for all processes

**For information**

- c) General RAC procedures

**RAC/44/2018/03**

**For discussion/agreement**

## **Item 6 – Requests under Article 77(3)(c)**

### **6.1 General occupational exposure issues**

- a) Feedback from the preparatory workshop on OEL

**For information**

### **6.2 Occupational exposure limits - opinion development**

- a) Nickel and its compounds  
b) Benzene  
c) Acrylonitrile

**For adoption**

## **Item 7 – Requests under Article 95 (3)**

None

## **Item 8 – Harmonised classification and labelling (CLH)**

### **8.1 General CLH issues**

### **8.2 CLH dossiers**

#### **A. Hazard classes for agreement without plenary debate (fast-track)**

2-methoxyethyl acrylate: physical hazards (flammable liquids), acute toxicity (all routes of exposure), skin corrosion, eye damage, respiratory / skin sensitisation

imiprothrin (ISO): acute toxicity (all routes of exposure), STOT RE, germ cell mutagenicity, environmental hazards

granulated copper: physical hazards, acute toxicity (all routes of exposure), STOT SE, skin irritation, skin sensitisation, STOT RE, germ cell mutagenicity, carcinogenicity, toxicity to reproduction

nitric acid...%: EUH071 (corrosive to the respiratory tract)

pymetrozine (ISO): environmental hazards

margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide]: acute toxicity (dermal and inhalation), skin/eye

irritation, skin sensitisation, STOT SE, serious eye damage/irritation, germ cell mutagenicity, carcinogenicity

ipconazole (ISO): physical hazards, acute toxicity (all routes of exposure), STOT SE, serious eye damage / eye irritation, skin corrosion / irritation, respiratory or skin sensitisation, germ cell mutagenicity, carcinogenicity, environmental hazards

L-(+)-lactic acid: physical hazards, acute toxicity (all routes of exposure), skin sensitisation, STOT RE, germ cell mutagenicity, carcinogenicity, toxicity to reproduction, environmental hazards

mefentrifluconazole: physical hazards (except explosives, self-reacting substances and oxidising solids), acute toxicity (dermal and inhalation), skin corrosion / irritation, serious eye damage / eye irritation, skin sensitisation, germ cell mutagenicity, carcinogenicity, environmental hazards

## **B. Hazard classes for agreement with plenary debate**

- 1) octamethylcyclotetrasiloxilane
- 2) branched hexatriacontane
- 3) 2-methoxyethyl acrylate
- 4) diisooctyl phthalate
- 5) imiprothrin (ISO)
- 6) silicon carbide (fibres fulfilling the WHO definition: diameter <3 µm, length > 5 µm and aspect ratio ≥ 3:1)
- 7) Granulated copper
- 8) nitric acid...%
- 9) pymetrozine (ISO)
- 10) Margosa, ext. [cold-pressed oil of Azadirachta indica seeds without shells extracted with super-critical carbon dioxide]
- 11) ipconazole (ISO)
- 12) ethofumesate (ISO) (±)-2-ethoxy-2,3-dihydro-3,3-dimethylbenzofuran-5-yl methanesulfonate
- 13) L-(+)-lactic acid; (2S)-2-hydroxypropanoic acid
- 14) 1,2-Benzenedicarboxylic acid, di-C8-10-branched alkylesters, C9-rich; [1] di-“isononyl” phthalate; [2] (DINP)
- 15) (2RS)-2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol; mefentrifluconazole
- 16) MCPA-thioethyl (from RAC 43)

***For discussion and adoption***

### **Item 9 – Restrictions**

#### **9.1 Restriction Annex XV dossiers**

- a) Opinion development
  - 1) Lead and lead compounds in shot – final draft opinion

***For adoption***

- 2) Substances used in tattoo inks and permanent make-up – first draft opinion

3) C9-C14 PFCAs, their salts and related substances– first draft opinion

***For discussion/agreement***

## **Item 10 – Authorisation**

### **10.1 General authorisation issues**

a) Update on incoming/future applications

***For information***

### **10.2. Authorisation applications**

a) Discussion on key issues

1. DBP\_AVX
2. Diglyme\_Omnichem
3. SD\_Olwerke

***For discussion***

b) Agreement on draft opinions

1. CT\_Hapoc (1 use)
2. CT\_Hapoc\_2 (1 use)
3. CT\_Hapoc\_3 (1 use)

***RAC/44/2018/04  
(Restricted)***

***For information***

4. DtC\_Wesco (1 use)
5. SC\_Wesco (1 use)
6. PCO\_Aviall (2 uses)

***For discussion and agreement***

7. PCO\_IP (2 uses)

***For discussion***

c) Adoption of final opinions

No opinions to be finalised at this meeting.

***For discussion and adoption***

### **10.3. Review reports**

a) Discussion on key issues

No review reports received for the key issues discussion

***For discussion***

- b) Agreement on draft opinions
  - 1. RR1\_DEHP\_VINYLOOP (2 uses)
  - 2. RR1\_DEHP\_PP (2 uses)

***For discussion***

**Item 11 – AOB**

**Item 12 – Action points and main conclusions of RAC-44**

Table with Conclusions and Action points from RAC-44

***For adoption***

## **PROVISIONAL TIMELINE FOR THE DISCUSSIONS AT RAC-44**

Please note that this timeline is provisional. Changes can be made before and during the meeting in order to accommodate the discussions.

### **First week**

#### **Tuesday 27 February: Afternoon session**

- Item 1 - Welcome and Apologies
- Item 2 - Adoption of the Agenda
- Item 3 - Declarations of conflicts of interest to the Agenda
- Item 5 - RAC Work Plan for Restriction, Authorisation and C&L processes
- Item 9 - Restrictions

#### **Wednesday 28 February: Morning session**

- Item 9 - Restrictions
- Item 10 - Authorisation applications

#### **Wednesday 28 February: Afternoon session**

- Item 10 - Authorisation applications

#### **Thursday 1 March: Morning session**

- Item 10 - Authorisation applications
- Item 6 - Requests under Article 77(3)(c )

#### **Thursday 1 March: Afternoon session**

- Item 6 - Request under Article 77(3)(c )

#### **Friday 2 March: Morning session**

- Item 6 - Request under Article 77(3) (c )

**Second week**

**Tuesday 6 March: Morning session**

- Item 1 - Welcome and Apologies
- Item 2 - Adoption of the Agenda
- Item 3 - Declarations of conflicts of interest to the Agenda
- Item 8 - CLH dossiers

**Tuesday 6 March: Afternoon session**

- Item 8 - CLH dossiers

**Wednesday 7 March: Morning session**

- Item 8 - CLH dossiers

**Wednesday 7 March: Afternoon session**

- Item 8 - CLH dossiers

**Thursday 8 March: Morning session**

- Item 8 - CLH dossiers

**Thursday 8 March: Afternoon session**

- Item 8 - CLH dossiers

**Friday 9 March: Morning session**

- Item 4 - Appointment of rapporteurs
- Item 8 - CLH dossiers

END OF RAC-44